Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Fluorouracil 67Leucovorin 61Oxaliplatin 49Irinotecan 31Capecitabine 23Cetuximab 22Bevacizumab 20Folfox protocol 13Radiotherapy 12Chemotherapy, Adjuvant 11Neoadjuvant Therapy 10Erlotinib Hydrochloride 7dehydroftorafur 5Trastuzumab 5Radiation 5Melphalan 5Magnetic Resonance Spectroscopy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5sargramostim 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Gene Expression Profiling 4Gefitinib 4Floxuridine 4Biopsy 4aldesleukin 3Sorafenib 3Semaxinib 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rectal Neoplasms × Diagnostic Imaging × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡